title: [Current treatment of AL amyloidosis].
abstract: AL amyloidosis is a plasma cell disorder characterized by the tissue accumulation of immunoglobulin light chains. The prognosis of AL amyloidosis is poor, with a median survival inferior to two years. Amyloid deposits, responsible for the clinical manifestations of this disease, can regress at least partially after the suppression of the production of amyloid precursors. Therefore, current treatment strategies in AL amyloidosis aim at reducing the plasma cell clones, using chemotherapy regimens applied in multiple myeloma. A combination of melphalan and prednisone is the standard therapy of AL amyloidosis, but its results remain disappointing. Intensive chemotherapy regimens, with high-dose melphalan followed by peripheral blood stem cell transplantation, lead to increased response rates and improved survival, but are complicated by severe short term morbidity and mortality. These regimens offer the best clinical perspectives for selected patients, until the introduction of innovative agents capable of interfering with amyloid fibril formation.
authors: Département de médecine, CHUV, Lausanne. Tibor.Kovacsovics@chuv.hospvd.ch
authors: T
authors: T
authors: Kovacsovics
mesh_terms: D000682:Amyloid; D000686:Amyloidosis / Q000145:classification* / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D009017:Morbidity; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000682:Amyloid; D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; C035222:amyloid protein AL; D008558:Melphalan; D011241:Prednisone